PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar Coralreefer1 (26.32) Submitted: 2/7/2012 8:45:42 AM : Underperform Start Price: $6.29 PDLI Score: -4.51

reliance on one product and its dividend has lessed over time. "Not good to put your apples in JUST one basket"

Featured Broker Partners


Advertisement